
Healthcare Global Enterprises Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Updated: 18 Sept 2026 • 10:27 am
Posted by:

Track the latest Healthcare Global Enterprises Ltd. share price on Univest. The Healthcare Global Enterprises Q2 results for the September 2026 quarter comes after a stretch where revenue has grown steadily even as net profit has bounced around, including one loss-making quarter. This Healthcare Global Enterprises Q2 results preview covers the results date pattern, qualitative expectations, the previous quarter, the year-ago base, and valuation, all from reported historical data only.
Healthcare Global Enterprises CMP Rs 693.45, up 0.92% on the day. 52-week range Rs 513.3 to Rs 799.71. Q1 FY27 (Jun26) revenue Rs 695 crore, net profit Rs 16 crore. Market cap Rs 10,360 crore.
As a hospital and oncology care operator, Healthcare Global Enterprises has kept its operating margin in a fairly tight band across the last five quarters, even though net profit has been more volatile, a distinction that matters heading into the Healthcare Global Enterprises Q2 results.
When Might the Healthcare Global Enterprises Q2 Results Be Announced
Listed companies must disclose quarterly financial results within 45 days of quarter-end under SEBI LODR norms. Applying that pattern to the September 2026 quarter, the Healthcare Global Enterprises Q2 results for FY27 would typically be expected between late October 2026 and mid-November 2026, in line with the company's past reporting timing.
No board meeting date has been confirmed as of this writing. Readers tracking the Healthcare Global Enterprises Q2 results should watch official NSE and BSE filings closer to the announcement date.
What to Expect From the Healthcare Global Enterprises Q2 Results
With Q2 FY27 not yet reported, expectations here remain qualitative. The key theme ahead of the Healthcare Global Enterprises Q2 results is the gap between a stable operating margin, which has stayed between 17.38% and 19.17% over the last five quarters, and a much more volatile net profit line that even turned negative in Dec25.
Ramp-up of newer hospital capacity, occupancy trends, and payer mix between cash and insurance patients are the qualitative factors most likely to influence how the Healthcare Global Enterprises Q2 results shape up relative to both the preceding and year-ago quarters.
Also read – Jagran Prakashan Q2 Results FY27 Preview
Previous Quarter: Healthcare Global Enterprises Q1 FY27 (Jun26) Performance
In Q1 FY27 (Jun26), Healthcare Global Enterprises reported revenue of Rs 695 crore, operating profit of Rs 122 crore, an operating margin of 17.55%, and net profit of Rs 16 crore. Revenue was the highest of the five reported quarters, even as net profit remained modest relative to the operating profit figure.
This Jun26 print is the latest actual sequential data point ahead of the Healthcare Global Enterprises Q2 results and forms the base for the quarter-on-quarter comparison in the September 2026 print.
The Base Quarter: Healthcare Global Enterprises Q2 FY26 (Sep25) for Comparison
The year-ago quarter for the Healthcare Global Enterprises Q2 results is Q2 FY26 (Sep25), when the company reported revenue of Rs 647 crore, operating profit of Rs 123 crore, an operating margin of 19.01%, and net profit of Rs 21 crore, the highest net profit among the five quarters shown.
Because Sep25 combined a strong margin with the highest net profit in the trailing data, it sets a relatively tough year-on-year comparison for the Healthcare Global Enterprises Q2 results this time.
Recent Trend Across the Last Five Quarters
Across the five reported quarters: Jun25 revenue was Rs 613 crore with a 17.62% margin and Rs 6 crore net profit; Sep25 was Rs 647 crore revenue with a 19.01% margin and Rs 21 crore net profit; Dec25 was Rs 633 crore revenue with a 17.38% margin but a net loss of Rs 8 crore; Mar26 was Rs 652 crore revenue with a 19.17% margin and Rs 4 crore net profit; and Jun26 was Rs 695 crore revenue with a 17.55% margin and Rs 16 crore net profit.
Revenue has trended gently higher across these five quarters while net profit has swung between a loss and a modest gain, a divergence that is central to reading the Healthcare Global Enterprises Q2 results whenever they land.
Check live Healthcare Global Enterprises stock data and financials on the Univest app
Key Factors to Watch Ahead of the Healthcare Global Enterprises Q2 Results
Occupancy and case mix across the hospital network, particularly in oncology and other high-value specialities, will influence both revenue growth and margin.
Below-the-operating-line items such as depreciation on new hospital capacity and finance costs have been the bigger driver of the swings in net profit, and that pattern is worth watching again in the Healthcare Global Enterprises Q2 results.
Also read – Jagsonpal Pharmaceuticals Q2 Results FY27 Preview
Progress on newer centres reaching operational break-even is a further qualitative factor that could shape the net profit outcome this quarter.
Valuation Snapshot Ahead of the Healthcare Global Enterprises Q2 Results
At the current market price of Rs 693.45, Healthcare Global Enterprises trades at a trailing PE of 215.31 times, with an EPS of Rs 3.22, a high multiple that reflects the company's currently thin net profit base relative to its market capitalisation.
The price-to-book ratio is 7.77 times against a book value of Rs 89.2 per share. Return on equity is low at 2.54%, and the debt-to-equity ratio is 1.3, indicating meaningful debt on the balance sheet. The company currently pays no dividend. Market capitalisation is Rs 10,360 crore, a figure worth keeping in view alongside the Healthcare Global Enterprises Q2 results.
What to Watch Around the Healthcare Global Enterprises Q2 Results Announcement
Investors should track the confirmed filing date on NSE and BSE, management commentary on hospital occupancy and new centre ramp-up, and whether net profit stabilises after the Dec25 loss.
Any change in payer mix or insurance realisation rates is likely to be discussed alongside the headline numbers when the Healthcare Global Enterprises Q2 results are released.
Conclusion
The Healthcare Global Enterprises Q2 results for the September 2026 quarter follow a period of steady revenue growth and a stable operating margin band, but a genuinely volatile net profit line that included one loss-making quarter, so the bottom line deserves closer attention than the top line alone.
As with any unreported quarter, the actual Healthcare Global Enterprises Q2 results should be confirmed through official exchange filings once announced rather than assumed from the historical pattern.
Track more Q2 FY27 results previews and stock research on Univest
Disclaimer: Univest Securities Private Limited is a SEBI-registered Research Analyst (Registration No. INH000013776). This article is for educational and informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Figures cited are historical, publicly disclosed quarterly financials and current market data; no specific Q2 FY27 results, estimates, or forecasts are implied. Please consult a SEBI-registered investment adviser and verify data independently before making any investment decision.
FAQs
When will the Healthcare Global Enterprises Q2 results for FY27 be announced?
Ans. The date has not been confirmed yet. Based on the 45-day SEBI LODR window and past reporting timing, the Healthcare Global Enterprises Q2 results are typically expected between late October and mid-November 2026, to be confirmed through NSE and BSE filings.
What was Healthcare Global Enterprises' revenue in the previous quarter?
Ans. In Q1 FY27 (Jun26), the company reported revenue of Rs 695 crore, an operating margin of 17.55%, and net profit of Rs 16 crore, the sequential base ahead of the Healthcare Global Enterprises Q2 results.
How did Healthcare Global Enterprises perform in the year-ago Q2 FY26 quarter?
Ans. In Q2 FY26 (Sep25), the company reported revenue of Rs 647 crore, an operating margin of 19.01%, and net profit of Rs 21 crore, the base quarter the Healthcare Global Enterprises Q2 results will be compared against.
What is Healthcare Global Enterprises' current valuation?
Ans. As of the data used in this preview, the stock trades at a PE of 215.31 times, a PB of 7.77 times, an ROE of 2.54%, and a market capitalisation of Rs 10,360 crore, figures relevant alongside the Healthcare Global Enterprises Q2 results.
Recent Articles

Intellect Design Arena Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
18 September 2026

Inspirisys Solutions Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
18 September 2026

Insecticides (India) Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
18 September 2026

Inox Wind Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
18 September 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Intellect Design Arena Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Inspirisys Solutions Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Insecticides (India) Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Inox Wind Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Hero MotoCorp Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
Popular this week
Heritage Foods Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





